Skip to content. | Skip to navigation

Personal tools

Yuzhuo Wang


Peer-Reviewed Papers = 159 |  Books and Chapters = 16


In Press

1. Wong J, Choi SYC, Liu R, Xu E, Killam J, Gout PW, Wang YZ. Potential therapies for infectious diseases based on targeting immune evasion mechanisms that pathogens have in common with cancer cells. Frontiers. in Cellular and Infection Microbiology (In Press)

2. Parolia A, Venalainen E, Xue H, Mather R, Lin D, Wu R, Pucci P, Rogalski J, Evans J, Feng F, Collins C, Wang YZ, Crea F. The long non-coding RNA, HORAS5, mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. Molecular Oncology. (In Press) (Wang YZ is co-senior author)


1. Flores-Morales A, Bergmann TB, Lavallee C, Batth TS, Lin D, Lerdrup M, Friis S, Xue H, Fazli L, Hansen KH, Bjartell A, Wang YZ, Olsen JV, Collins CC and Iglesias-Gato D. Proteogenomic characterization of patient derived xenografts revealed the role of REST in castration-resistant neuroendocrine prostate cancer. Clin Can Res 15;25(2):595-608, 2019.

2. Li Y, Zhang Q, Lovnicki J, Chen R, Fazli L, Wang YZ, Gleave M, Huang J, Dong X. SRRM4 gene expression correlates with neuroendocrine prostate cancer.  Prostate. 79(1):96-104, 2019.

3. Guo Y, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan A, Ba-Alawi W, Zhang S, Mahamud O, Vellanki R, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin C, Tsao MS,,  Wouters B,  Fazli L, Feng F, Ellis L, Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang YZ, He HH,  ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications 10(1): 278, 2019. (Wang YZ is co-senior author)



1. Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y. Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1587. 

2. Liang P, Guo J, Li S, Guan Q, Vanderheyden T, So A, Wang Y, Chen T, Du C. Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune®) in TRAMP Mice. Evid Based Complement Alternat Med. 2018 May 14;2018:9707543. 

3. Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 Jun 1;7(6). 

4. Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. Eur Urol. 2018 Jun;73(6):949-960. 
5. Qu S, Ci X, Xue H, Dong X, Hao J, Lin D, Clermont PL, Wu R, Collins CC, Gout PW, Wang Y. Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. Br J Cancer. 2018 Mar 20;118(6):802-812.

6. Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, Collins CC, Gleave ME, Gout PW, Wang Y. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. Int J Cancer. 2018 Jul 15;143(2):419-429. PMID: 29441566 

7. Liu Y, Ji X, Tong W. W. L, Askhatova D, Cheng H, Wang YZ, Shi J. Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angew Chem Int Ed Engl. 5;57(6):1510-1513, 2018.

8. Xue H , Wang YZ, MacCormack TJ, Lutes T, Rice C, Davey M, Dugourd D, Ilenchuk TT, and Stewart JM. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. Journal of Cancer. 9(17): 3196-3207, 2018.

9. Ci X, Hao J, Dong X, Choi S, Xue H, Wu R,  Qu S, Gout PW, Zhang F, Haegert A, Fazil L, Crea F, Ong C, Zoubedi A, He H, Gleave M, Collins CC, Lin D, Wang YZ. Heterochromatin Protein 1a Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Research. 15;78(10):2691-2704, 2018. 

10. Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H,  Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zouveidi A, Collins CC, Gleave ME, Lin D, Wang YZ. Patient-derived hormone-sensitive prostate cancer xenograft models reveal GRB10 as an AR-repressed gene driving the development of castration-resistant prostate cancer Eur. Urol. 73(6):949-960, 2018.

11. Nabavi N, , Wei J, Lin D, Collins CC, Gout PW, Wang YZ. Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-induced to Patient-derived Cancer Xenografts. Front. Genet. 2018 Jul 4;9:232.

12. Ci X, Lin D, Wang YZ. Using NEPC cell NCI-H660 for in vitro assays. Nature Protocol Exchange, 2018.

13. Mather RL, Wang YZ, Crea F.  Is HOTAIR really involved in neuroendocrine prostate cancer differentiation? Epigenomics. 10(10):1259-1261, 2018. PMID: 30238772.

14. Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamyabi A, Nakouzi N A, Hayashi T, Choi S, Wang YZ, Frees S, Daugaard M, Oo H Z, Fisel P, Schwab M, Schaeffeler E, Douglas J, Gibb EA, Hennenlotter J, Bedke J, Fazli L, Stenzl A, and Black PC. Selective inhibition of the lactate transporter MCT4 reduces growth of invasive bladder cancer. MCT. 17(12):2746-2755, 2018.

15. Luo F, Yang K, Wang YZ, Lin D. TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis. Neoplasma. 65(5):815-821, 2018.



1. Zhang P, Wang D , Zhao Y , Ren S , Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao SM, Li Y, Lin D, Wang YZ, Wang L, Chen Y , Sun Y, Wang C, Huang H, Intrinsic BET inhibitor resistance in prostate cancer caused by SPOP mutation-mediated BET protein stabilization. Nature Medicine. 23(9):1055-1062, 2017.

2. Wilkes DC, Sailer V,Xue H, Cheng H, Collins CC, Gleave M, Wang YZ, Demichelis F, Beltran H, Rubin M, Richman D. A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harb Mol Case Stud. 3(5). pii: a001487, 2017.

3. Davies AH,  Wang YZ, Zoubeidi A. Patient-Derived Xenografts: A Platform for Accelerating Translational Research in Prostate Cancer.  Molecular and Cellular Endocrinology. pii: S0303-7207(17)30182-X, 2017.  

4. Nabavi N, Nur Saidy R, Haegert A, Parolia A, Xue H, Wang Y, Wu R, Dong X, Collins C, Crea F, Wang YZ. miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Scientific Report. 22;7(1):4079, 2017. 

5. Mo F, Lin D, Takhar  M, Ramnarine VR, Dong X, Bell R H, Volik S, Wang K, Xue H, Wang Y, Haegert A, Anderson S,  Brahmbhatt S,  Erho N, Wang X, Gout PW,  Morris J, Karnes RJ, Den R,  Klein EA, Schaeffer EM, Ross A, Ren S, Sahinalp SC, Li Y, Xu X, Wang J, Wang J, Gleave M, Davicioni E, Sun Y,  Wang YZ, Collins CC. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology.  pii: S0302-2838(17)30166-5, 2017. (Co-senior author) 

6. Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Wang  YZ, Collins C, Dong X. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. European Urology. 71(1):68-78, 2017.  

7. Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi S, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang YZ.  Metabolic Heterogeneity Signature of Primary Treatment Naïve Prostate Cancer. Oncotarget, 2017.  

8. Bishop J, Thaper D, Vahid S, Davies A,  Ketola K,  Kuruma H, Jama R, Nip K, Johnson F, Wyatt A, Fazli L, Gleave M, Lin D, Rubin M, Collins C, Wang YZ, Beltran H, and Zoubeidi A. The master neural transcription factor BRN2 is an androgen receptor suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discovery. 7(1):54-71, 2017. 

9. Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget. Feb 7;8(6):9617-9633, 2017. PMID: 28038451  


1. Wang YZ, Wang JX, Xue H, Lin D, Dong X, Gout PW, Gao X, Pang J. Subrenal capsule grafting technology in human cancer modeling and translational cancer research.  Differentiation91(4-5):15-9, 2016. 

2. Hao J, Chiang YT, Gout PW, Wang YZ.  Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence. Frontiers in Bioscience. 8:44-55, 2016. 

3. Crea F, Quagliata L, Michael A, Liu H, Frumento P, Azad A. A, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S, Wang Y, Parolia A, Lennox K.A, Lam W, Gleave M, Chi Kim, Pandha H, Wang YZ, Helgason CD. Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Molecular Oncology. 10(5):693-703, 2016. 

4. Choi  SYC, Xue H, Wu R, Fazli L, Lin D, Collins CC, Gleave M, Gout PW, Wang YZ. The MCT4 Gene: a Novel, Potential Target for Therapy of Advanced Prostate Cancer. Clin Cancer Research. 22(11):2721-33, 2016.  

5. Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, Roemer M, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, Bonin F, Thorner AR, Sun H, Gascoyne RD, Pinkus GS, Hummelen P, Wulf G, Aster JC, Weinstock D, Monti S, Rodig S,  Wang YZ, and Shipp M A. Diffuse Large B-cell Lymphoma Patient-derived Xenograft Models Capture the Molecular and Biologic Heterogeneity of the Disease. Blood. 127(18): 2203-13 , 2016.  

6. Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZ, Parolia A, Wu R, Xue H, Wang Y, Ding J, Thu KL, Lam WL, Shah SP, Collins C, Wang YZ, Helgason CD: Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 8:16, 2016. 

7. Crea F, Venalainen E, Ci X, Cheng H, Pikor L, Parolia A, Xue H, Nur Saidy NR, Lin D, Lam W, Collins C, Wang YZ. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics. 8(5):721-31, 2016 . PMID: 27096814. 

8. Sun X, Clermont PL, Jiao W, Helgason CD, Gout PW, Wang YZ, Qu S. Elevated expression of the centromere protein-A (CENP-A)-encoding gene as a prognostic and predictive biomarker in human cancers. Int J of Cancer. 139(4):899-907, 2016.   

9. Lin D, Wang X, Choi S, Ci X, Dong X, Wang YZ. Immune phenotypes of prostate cancer cells: evidence of EIT?  Asian Journal of Urology. 3(4): 195-202, 2016. 

10. Nabavi N, Bennewith KL, Churg A, Wang YZ, Collins CC, Mutti L. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes Cancer. 7(11-12):340-354, 2016

11. Luk I, Shrestha R, Xue H ,Wang Y, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins C, Zoubeidi A, Gleave M, Gout PW, Wang YZ. BIRC6-targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer. Clin Cancer Research. clincanres-0718, 2016. 

12. Somasekharan SP, El-Naggar, Sorensen P, Wang YZ and Cheng H. An Aqueous Extract of Marine Microalgae Exhibits Anti-Metastatic Activity through Preferential Killing of Suspended Cancer Cells and Anti-Colony Forming Activity. Evidence-Based Complementary and Alternative Medicine, 2016.



1. Crea F, Di Paolo A, Liu HH, Polillo M, Clermont PL, Guerrini F, Ciabatti E, Ricci F, Baratè C, Fontanelli G, Barsotti S, Morganti R, Danesi R,  Wang YZ, Petrini M, Galimberti S, Helgason CD. Polycomb genes are associated with response to imatinib in chronic myeloid leukemia.  Epigenomics.  7(5):757-65, 2015. 

2. Fornaro L, Faviana P, De Gregorio V, Vivaldi C, Paolicchi E, Masi G, Loupakis F, Sensi E, Lupi C, Fontanini G, Wang YZ, Danesi R, Falcone A, and Crea F. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer.15(1): 874, 2015.  

3. Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, Park, K.Banfelder, J.Prandi, D.Madhukar, N. Zhang, T. Padilla, J. Greco, N.McNary, T. J. Herrscher, E.Wilkes, D. MacDonald, T. Y. Xue, H. Vacic, V. Emde, A. K. Oschwald, D. Tan, A. Y. Chen, Z. Collins, C. Gleave, M. E. Wang, Y.Z. Chakravarty, D. Schiffman, M. Kim, R. Campagne, F. Robinson, B. D. Nanus, D. M. Tagawa, S. T. Xiang, J. Z. Smogorzewska, A. Demichelis, F. Rickman, D. S. Sboner, A. Elemento, O. Rubin, M. A: Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 1(4):466-474, 2015.  

4. El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TG, Negri GL, Somasekharan SP, Corkery DP, Tirode F, Mathers J, Khan D, Kyle AH, Baker JH, LePard NE, McKinney S, Hajee S, Bosiljcic M, Leprivier G, Tognon CE, Minchinton AI, Bennewith KL, Delattre O,  Wang YZ, Dellaire G, Berman JN, Sorensen PH. Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. Cancer Cell. 27(5):682-97, 2015. 

5. Akamatsu, S., Wyatt, A. W., Lin, D., Lysakowski, S., Zhang, F., Kim, S., Tse, C, Wang, K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazil L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin M, Beltran H, Zoubeidi A,  Wang YZ, Gleave ME & Collins, C. C. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports. 12(6):922-36, 2015. 

6. Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang YZ, Helgason CD. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clinical Epigenetics. 7:40  doi:10.1186/s13148-015-0074-4. 2015. 

7. Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo J, Wang YZ, Xu Y. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget. 6(8):6092-104, 2015.  

8. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson S, McConeghy B, Shukin R, Bazov J, Youngren J, Paris PL, Thomas GV, Small EJ, Wang YZ, Gleave ME, Collins CC, Chi K. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of the therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 21(10):2315-24, 2015.

9. Parolia A, Crea F, Xue H, Wang Y, Mo F, Ramnarine VR, Liu H, Lin D, Saidy R, Clermont PL, Cheng H, Collins C,  Wang YZ, Helgason CD. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity  in vivoMolecular Cancer . 21;14:46, 2015. 

10 . Crea F, Saidy NRN, Collins C, Wang YZ. The epigenetic/non-coding origin of tumour dormancy. Trends Mol Med. 21(4): 206-211, 2015.

11. Somasekharan SP, EI-Naggar A, Cheng H, Leprivier G, Hajee S, Grunewald T, Ng T, Delattre O, Evdokimova V,  Wang YZ, Gleave M, and Poul H Sorensen PH. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1 . J Cell Biology. 208(7): 913-929,  2015. 

12. Yoshi Y,  Loriot Y, Beraldi E, Zhang F, Wyatt A, Mo F, Zhou, T, Kim Y, Monia B, Macleod R, Fazli L, Wang YZ, Collins C, Zoubeidi A, Gleave M. Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and its Splice Variants Suppress Enzalutamide Resistant Prostate Cancer Cell Growth. Clinical Cancer Research. 21(7):1675-87, 2015. 

13. Xie N, Cheng H, Lin D, Liu L L, Yang O, Fazli L, Jia L, Gleave M, Wang YZ, Rennie P, Dong X. The Expression of Glucocorticoid Receptor is Negatively Regulated by Active Androgen Receptor Signaling in Prostate Tumors. International Journal of Cancer. 136(4):E27-38. 2015.  

14. Lin D, Dong X, Wang K, Wyatt A, Crea F,  Xue H, Wang Y, Wu R, Bell R, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave M, Collins C, Wang YZ. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget. 6(3):1806-20, 2015.


1. Hodgson MC, Deryugina EI, Suarez E, Lopez SM, Lin D, Xue H, Gorlov IP, Wang YZ, Agoulnik IU. INPP4B suppresses prostate cancer cell invasion. Cell Commun Signal.12(1):61, 2014. PMID: 25248616.

2. Choi SYC, Lin D, Gout PW, Collins CC, Xu Y, Wang YZ.  Lessons from patient-derived xenografts for better in vitro modeling of human cancer” Advanced Drug Delivery Reviews. 79-80C:222-237, 2014. PMID: 25305336. 

3. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, Shumansky K, Rosner J, McPherson A, Nielsen C, Roth A, Lefebvre C, Bashashati A, deSouza C, Siu C, Edwards J, Oloumi A, Osako T, Bruna A, Sandoval J, Algara T, Greenwood W, Leung K,  Cheng H, Xue H, Wang YZ, Lin D, Mungall A, Moore R, Zhao Y, Lorette J, Nguyen L, Huntsman D, Eaves C, Hansen C, Marra M, Caldas C, Shah SP, Aparicio S. Dynamics of genomic clonal evolution in breast cancer patient xenografts at single cell resolution. Nature. 518(7539):422-6, 2015. PMID: 25470049 

4. Wyatt A, Mo F, Wang K, McConeghy B, Brahmbhatt S,  Jong L, Mitchell D, Johnston R, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk A, McPherson A, Shukin R, Bell R, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan A, Mehra R, Lin D, Wang YZ, Fazli L,  Gleave M, Volik S, and Collins C. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biology. 15(8):426, 2014. PMID: 25155515 

5. Xie Y, Liu S, Lu W, Yang Q, Carver BS, Li E, Wang YZ, Fazli L, Gleave M, and Chen Z. Crosstalk between nMET and SOX9/β-Catenin Correlates with Castration Resistant Prostate Cancer. Mol Endocrinology. 28(10):1629-39, 2014.

6. Luk I, Xue H, Cheng H, Lin D, Gout PW, Fazli L, Collins C, Gleave M,  Wang YZ. The BIRC6 gene as a novel target for therapy of prostate cancer: Dual targeting of Inhibitors of Apoptosis. Oncotarget. 30;5(16):6896-908, 2014. 

7. Lapuk AV, Volik SV, Wang YZ, Collins CC. The role of mRNA splicing in prostate cancer. Asian J Androl 16(4): 515-21, 2014. PMID: 24830689. 

8. Wang K, Shrestha R, Wyatt A, Reddy A, Lehár J, Wang YZ, Lapuk A, Collins C. A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines. PLoS ONE. 9(7): e103050, 2014.

9. Mo, F., Wyatt, A.W., Sun, Y., Brahmbhatt, S., McConeghy, B.J., Wu, C.,  Wang, YZ., Gleave, M.E., Volik, S.V.,  Collins, C.C.  Systematic identification and characterization of RNA editing in low coverage sequence data from prostate tumors.  PLoS ONE9 (7): 101431, 2014. 

10. Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, Wang Y, Lin D, Lam W, Farrar WL, Isogai T,  Morant R, Castori-Eppenberger S, Chi K, Wang YZ, and Helgason C. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget. 5(3):764-74, 2014. PMID: 24519926.   

11. Chiang YT, Gout PW. Collins CC, Wang YZ, Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification. Asian Journal of Andrology. 16(4): 545–548, 2014. PMID: 2458945.  

12. Lin D, Xue H, Wang Y, Wu R, Watahiki A, Dong X, Cheng H, Wyatt AW, Collins CC, Gout PW, Wang YZ. Next generation patient-derived prostate cancer xenograft models. Asian Journal of Andrology. 2014 May-Jun; 16(3): 407-41. PMID: 24589467.

13. Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang YZ. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget. 30;5(2):451-61, 2014. PMID: 24448395.  

14. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Cull A, Fazli L, Sharma M, Beltran H, Rubin MA, Cox ME, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang YZ. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Research. 74(4):1272-82, 2014. PMID: 24356420. 

15. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Cull A, Fazli L, Sharma M, Beltran H, Rubin MA, Cox ME, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang YZ. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Research. 74(4):1272-82, 2014. PMID: 24356420.  

16. Zhang C, Kho YS, Wang Z, Chiang YT, Ng GKH, Shaw PC, Wang YZ, Qi RZ. Transmembrane and Coiled-coil Domain Family 1 Is a Novel Protein of the Endoplasmic Reticulum. PLoS ONE. 9(1):e85206, 2014.

17. Qu, S, Wang K, Xue H, Wang Y, Wu R ,  Liu C,  Gao A,  Gout PW, Collins C, Wang YZ . Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.  Molecular Oncology. 2014;8(2):311-22. PMID: 24388358

18. Svensson C, Ceder J, Gato D, Chuan YC, Pang J, Bjartell, A, Martinez R, Bott L, Helczynski L, Ulmert D, Wang YZ; Niu, YJ, Collins C, Morales A. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Research. 42(2):999-1015, 2014. PMID: 24163104. 

19. Crea F, Clemont PL, Parolia, A, Wang YZ, Helgason CD. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer and Metastasis Reviews. 33:1-16, 2014. PMID: 24346158.  


1. Wang K, Wang YZ, Collins CC. Chromoplexy: a new paradigm in genome remodeling and evolution.   Asian Journal of Andrology. 15(6):711, 2013. PMID: 23974363

2. Zhang H, Qi C, Wang A, Yao B, Li L, Wang YZ, Xu Y. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. Journal of Experimental & Clinical Cancer Research. 32:77, 2013.

3. Nakamura H, Wang Y, Xue H, Romanish MT,  MagerDL, Helgason CD, Wang YZ. Genistein vs. ICI 182, 780: an Ally or Enemy in Metastatic Progression of Prostate Cancer. Prostate. 73:1747-1760, 2013. PMID:  24038102

4. Choi SY, Collins CC, Gout PW, Wang YZ. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol. 230(4): 350-5, 2013. PMID: 23729358 

5. Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Rocha F, Ayala R, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares JH, Fregnani G, Soares FA, Flanagan A, Reynolds P, Arceci RJ, Triche TJ, Wang YZ, Strauss SJ, Sorensen PHB. ERBB4 is a novel driver of metastasis in Ewing sarcoma. EMBO Mol Med. 5(7): 1087-102, 2013. PMID: 23681745  

6. Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang Y, Gleave M, Dong X. Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control. J Clin Endocrinol Metab. 98(7):2887-96, 2013. PMID: 23666965   

7. Watahiki A, Macfarlane RJ, Gleave M, Crea F, Wang YZ, Helgason CD, Chi K. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. International Journal of Molecular Sciences. 14(4):7757-70, 2013. PMID: 23574937 

8. Wyatt AW, Mo F, Wang YZ, Collins CC. The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian Journal of Andrology. 15(3):301-8, 2013. PMID: 23503423  

9. Lin D, Gout PW, Wang YZ. Lessons from in vivo models of castration-resistant prostate cancer. Curr Opin Urol. 23(3):214-9, 2013. PMID: 23385975. 

10. Low C, Luk I, Lin D, Dong, X, Yang K, Xu Y, Gleave M, Gout PW, Wang YZ. BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells. PLOS ONE. 8(2): e55837, 2013. PMID: 23409057 

11. Dong X, Lin D, Low C, Vucic E, English J, Yee J, Murray N, Lam W, Ling V, Lam S; Gout PW, Wang YZ. Elevated expression of BIRC6 protein in non-small cell lung cancers is associated with cancer recurrence and chemoresistance.  J Thorac Oncol. 8(2):161-70, 2013. PMID: 23287853 

12. Johnson DT, Luong R, Lee SK, Peng Y, Shaltouki A, Lee JT, Lin D, Wang YZ, Sun Z. Deletion of leucine zipper tumor suppressor 2 (lzts2) increases susceptibility to tumor development. J Biol Chem. 288(6):3727-38, 2013. PMID: 23275340. 

13. Duan Z, Zou JX, Yang P, Wang YZ, Borowsky AD, Gao AC, Chen HW. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate. 73(5):455-66, 2013. PMID: 23038103. 


1. Li L, Xie H, Liang L, Gao Y, Zhang D, Fang L, Lee SO, Luo J, Chen X, Wang X, Chang LS, Yeh S, Wang YZ, He D, Chang C. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis. 34(2):257-67, 2012. PMID: 23104178.  

2. Becker-Santos DD, Guo Y, Ghaffari M, Vickers ED, Lehman M, Altamirano-Dimas M, Oloumi A, Furukawa J, Sharma M, Wang YZ, Dedhar S, Cox ME. Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis. 33(12):2558-67, 2012. PMID: 23027626 

3. Wu C, Wyatt AW, McPherson A, Lin D, McConeghy BJ, Mo F, Shukin R, Lapuk AV, M Jones SJ, Zhao Y, Marra MA, Gleave ME, Volik SV,  Wang Y, Sahinalp SC, Collins CC. Poly-gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes Cancer. 2012 Dec;51(12):1144-53. PMID: 22927308 

4. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R,  Wang YZ, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 227(3):286-97, 2012. PMID: 22553170. 

5. Ricke EA, Williams K, Lee YF, Couto S, Wang YZ, Hayward SW, Cunha GR, Ricke WA. Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis. 33(7): 1391-8, 2012. PMID: 22535887. 

6. Choi SY, Gout PW, Collins CC, Wang YZ, Epithelial Immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation. 83(5):293-8, 2012. PMID: 22472059.  

7. Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Gleave ME, Bertino JR, Lubin M, Wang YZ. Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenine Phosphorylase (MTAP), an Exploitable Tumor Target. Mol Cancer Ther. 11(3):775-83, 2012. PMID: 22252602. 

8. Gout PW, Wang YZ. Drug sensitivity testing for personalized lung cancer therapy. J Thorac Dis4(1):17-8, 2012. PMID: 22295162. 


1. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW,  Wang YZ. MicroRNAs Associated with Metastatic Prostate Cancer. PLOS ONE. 6(9):e24950, 2011. PMID: 21980368. 

2. Tung WL, Wang Y, Gout PW, Liu DM, Gleave M, Wang YZ. Use of Irinotecan for Treament of Small Cell Carcinoma of the Prostate. The Prostate. 71 (7):675-681, 2011. PMID: 20949523.  

3. Nakamura H, Wang Y,  Kurita T, Adomat  H,  Cunha  GR,  Wang YZ. Genistein increases Epidermal Growth Factor Receptor signaling and promotes tumor progression in advanced human prostate cancer.  PLoS ONE. 6(5): e20034, 2011. PMID: 21603581 

4. Du C, Wang YZ. The immunoregulatory mechanisms of carcinoma for its survival and development. Journal of Experimental & Clinical Cancer Research. 30: 12, 2011 PMID: 21255410. 

5. Kortmann UK, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston A, O’Connor MJ, Huntsman DG, Wang YZ, Gilks B. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Research. 17:783-791, 2011. 

6. Espinosa I, Edris B, Lee CH, Cheng HW, Gilks CB, Wang YZ, Montgomery KD, Varma S, Li R, Marinelli RJ, West RB, Nielsen T, Beck AH, van de Rijn M. CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. Am J Pathol. 179(4):2100-7, 2011. PMID: 21854753.   

7. Hu P, Chu GCY, Yang H, Luthringer D, Prins G, Habib F, Wang YZ, Wang R, Chung LWK,  Zhau HE. Multiplexed Quantum Dot Labeling of Activated c-Met Signaling in Castration-Resistant Human Prostate Cancer. PLoS ONE. 6(12): e28670, 2011. PMID: 22205960   

8. Beltran H, Rickman DS, Park K, Sboner A, MacDonald TY, Wang Y, Chae SS, Dheikh K, Terry S, Tagawa ST, Dhir R, Nelson J, de la Taille A, Allory Y, Gerstein MB, Perber S, Pienta K, Chinnaiyan A, Wang YZ, Collins C, Gleave M, Demichelis F, Nanus DM, Rubin MA. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of Aurora Kinase as a Therapeutic Target. Cancer Discovery. 1(6):487-95, 2011.  

9. Stany MO,  Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D,  Gout PW,  Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. PLoS ONE. 6(7): e21121, 2011. PMID: 21754983.   

10. Kuchenbauer F, Mah SM, Heuser M, McPherson A, Ruschmann J,  Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A,  Eaves CJ,  Watahiki A, Wang YZ,  Aparicio SA, Ganser A,  Krauter J, Dohner H, Dohner K, Marra MA, Carmargo FD, Palmgvist L, Buske C, Humphries RK. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood. 118(12):3350-8, 2011. PMID: 21628414.  

11. Terry J,  De Luca A, Leung S, Peacock G, Wang YZ,  Elliot WM, Huntsman D. Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and non-squamous subtypes. Arch Pathol Lab Med. 135(4):433-9, 2011. 

12. Ip W, Wellman-Labadie O, Tang L, Su M, Yu R, Dutz J, Wang YZ, Huang S, Zhang X, Huang C, Zhou Y. Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. Journal of Cutaneous Medicine and Surgery.15 (2):103-110, 2011. PMID: 21477558. 



1. Cheng H, Clarkson PW, Gao D, Pacheco M, Wang YZ, Nielsen TO. Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor. Sarcoma, 2010. PMID: 20981142.  

2. Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW, Squire J, Wang YZ. Development of Metastatic and Non-Metastatic Tumor Lines From a Patient’s Prostate Cancer Specimen - Identification of a Small Subpopulation With Metastatic Potential in the Primary Tumor. The Prostate .70(15):1636 -1644, 2010. PMID: 20564316.  

3. Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Current Oncology. 17 (3): 9-16, 2010. PMID: 20567622.  

4. Niu Y, Chang NY, Yeh STM, Ma WL, Wang YZ, Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene. 29(25): 3593-604, 2010. PMID: 20440270.  

5. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung J K, Watt K, Tam T, Yang YC, Bañuelos CA, Williams D E, McEwan I, Wang YZ, Sadar MD. Regression of castrate-recurrent prostate cancer by a small molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell.17, 535–546, 2010. PMID: 20541699. 

6. Chiu H, Yong T MK, Wang J, Wang Y, Vessella RL, Ueda T, Wang YZ, and Sadar MD. Induction of Neuronal Apoptosis Inhibitory Protein Expression in Response to Androgen Deprivation in Prostate Cancer. Cancer Lett. 292: 176–185, 2010. PMID: 20044205.  

7. Dong X, Guan J, English J, Flint J, Yee J, Evans K, Murray N, MacAulay C, Ng R, Gout PW, Lam W, Laskin J, Ling V, Lam S, Wang YZ. Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Research.16:1442-1451, 2010. PMID: 20179238. 

8. McPherson S, Hussain S, Balanathan P, Hedwards S, Niranjan B, Grant M, Chandrasiri U, Toivanen U, Wang YZ, Taylor R, Risbridger G. Estrogen receptor beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen-independent and TNFα-mediated. PNAS. 107(7): 3123-3128, 2010.  PMID: 20133657. 



1. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang YZ, H. Huang. Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer. Cancer Research. 69(21):8386-94, 2009. PMID: 19826044.  

2. Guan J, Lo M, Dockery P, Mahon S, Karp C, Buckley A, Lam S,  Gout PW, Wang YZ. The xc- Cystine Transporter as a Therapeutic Target for Small Cell Lung Cancer: Use of Sulfasalazine. Cancer Chemotherapy and Pharmacology. 64(3): 463-72, 2009. PMID: 19104813. 

3. Lo M, Wang YZ, Gout PW. The xc- Cystine/Glutamate Antiporter: A Potential Target for Therapy of Cancer and Other Diseases: Yet Another Cytotoxic Anticancer Approach? J Cell Physiol. 220(2): 533-534, 2009. PMID: 18181196.  

4. Romanish MT, Nakamura H, Lai CB, Wang YZ, Mager DL. A novel protein isoform of the multicopy human NAIP gene derives from intragenic Alu AINE promoter. PLoS ONE. 4(6): e5761, 2009. PMID: 19488400. 



1. Lin D, Watahiki A, Bayani J, Zhang F, Liu FL, Ling V, Sadar M, English J, Fazli L, So A, Gout P, Gleave M, Squire JA and Wang YZ. ASAP1, a Gene at 8q24, is Associated with Prostate Cancer Metastasis. Cancer Research.  68: 4352-4359.  2008. PMID: 18519696. 

2. Press JZ, Kenyon JA, Xue H, Miller MA, de Luca A, Miller DM, Huntsman DG, Gilks CB, McAlpine JN and Wang YZ. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gyn Oncol. 110: 256-264, 2008. PMID: 18547621.  

3. Lo M, Ling V, Wang YZ, Gout PW. The xccystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. British J Cancer. 99: 464-472, 2008. Cited by 68). PMID: 18648370. 

4. Al-Romaih K, Sadikovi B, Yoshimoto M, Wang YZ, Zielenska M,  Squire JA. Decitabine induced demethylation of 5 CpG-island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 10. 471-80, 2008. PMID: 18472964.   

5. Ricke WA, McPherson SJ, Cunha GR, Wang YZ, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by  in situ estrogen production and estrogen receptor alpha-signaling. The FASEB Journal. 22(5):1512-20, 2008. PMID: 18055862. 

6. Lo M, Wang YZ, Gout PWThe Xc- Cystine/Glutamate Antiporter: a Potential Target for Therapy of a Variety of Diseases. Journal of Cellular Physiology. 215 (3):593-602, 2008. PMID: 18181196. 


1. Doxsee D, Gout P, Kurita T, Lo M, Buckley A, Wang Y, Xue H, Karp C, Cutz JC, Cunha G, and Wang YZ. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 67 (2): 162-171, 2007. PMID: 17075799. 

2. Verras M, Lee J, Xue H, Li TH, Wang YZ, Sun Z. The Androgen Receptor Negatively Regulates the Expression of c-Met, Implications for a Novel Mechanism of Prostate Cancer Progression. Cancer Research. 67 (3): 967-975, 2007. PMID: 17283128. 

3. Ricke WA, Wang YZ, Cunha GR. Steroid hormones and carcinogenesis of the prostate:  The role of estrogens. Differentiation.  75: 871-882, 2007. PMID: 17924963  

4. Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad MCutz JC, Xue H, Zielenska M,  Wang YZ, Squire JA. Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation. Cancer Cell International. 7:14, 2007. PMID: 17845729. 

5. Ishii OK, Kanda H, Kanai M, Arima K, Wang YZ, Sugimura Y. Bisphenol A induces permanent squamous change in mouse prostatic Epithelium. Differentiation. 75: 745–756, 2007. PMID: 17459086 



1. Cutz JC, Guan J, Bayani J, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire J,  Gout PW, Lam S,  Wang YZ. Establishment in SCID Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression-Related Changes. Clin Cancer Research. 12(13): 4043-4054, 2006. PMID: 16818704. 

2. Sobel RE, Wang YZ, Sadar MD. Molecular Analysis and Characterization of PrEC, Commercially Available Prostate Epithelial Cells. In Vitro Cellular & Developmental Biology - Animal. 42:33–39, 2006. PMID: 16618209 

3. Ricke WA, Ricke EA, Simko J, Wang YZ, Hayward SW, Cunha GR. Steroid Hormones Stimulate Human Prostate Cancer Progression and Metastasis. Int J Cancer. 118(9): 2123-2131, 2006. PMID: 16331600.



1. Wang Y, Xue H, Mawji R, Chen WG, Hayward SW, Gilks CB, Sadar MD, Gout PW, Cunha GR, Wang YZ. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab. Invest. 85: 1392-1404, 2005 (Cover art and features inside Lab. Invest.) (Cited by 90). PMID: 16155594.  

2. Cunha GR, Place NJ, Baskin L, Conley A, Weldele M, Cunha TJ, Wang YZ, Cao M, Glickman SE. The Ontogeny of the Urogenital System of the Spotted Hyena. Biol Reprod. 73: 554-564, 2005. PMID: 15917348. 

3. Wang YZ, Revelo MP, Sudilovsky D, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate. 64, 149-159, 2005. PMID: 15678503.  

4. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gyn Oncol. 96 (1): 48-55, 2005. PMID: 15589579. 



1. Cunha GR, Riche W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T. Hormonal, Cellular, and Molecular Regulation of Normal and Neoplastic Prostatic Development. Journal of Steroid Biochemistry and Molecular Biology. 92: 221-236, 2004. PMID: 15663986. 



1. Rubenstein NM, Cunha GR, Wang YZ, Campbell KL, Conley AJ, Catania KC, Glickman SE, Place NJ. A peniform clitoris in New World moles with and without 'ovotestes'. Reproduction. 126: 713-719, 2003. PMID: 14748690. 

2. Sharma M, Li X, Wang YZ, Zarnegar M, Huang CY, Palvimo JJ, Lam B, Sun Z. A novel PIAS-like protein, hZimp10, acts as the androgen receptor coactivator and forms a complex with SUMO-1 at replication foci. EMBO J. 22 (22): 6101-6114, 2003. PMID:14609956.  

3. Cunha GR, Hayward SW, Wang YZ. W. A. Ricke. Stromal micro-environment in carcinogenesis of the prostate. Int J Cancer. 107: 1-10, 2003. PMID: 12925950. 

4. Cunha GR, Wang YZ,  Place NJ, Liu W, Baskin L, Glickman SE. The Urogenital System of the Spotted Hyena (Crocuta crocuta): A Functional Histological Study. J Morphology. 256 (2): 205-18, 2003. PMID: 12635111. 

5. Staack A, Kassis AP, Olshen A, Wang YZ, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW.  Quantitation of apoptotic activity following castration in human prostatic tissue in vivoProstate. 54: 212-219, 2003. PMID: 12518326. 



1. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation. 70 (9-10): 473-85, 2002. PMID: 12492490. 

2. Day KC, McCabe MT, Zhao X, Wang YZ, Phillips J, Ried T, Davis JN, KuKuruga MA, Cunha GR, Hayward SW, Day ML. Homozygous disruption of the retinoblastoma gene promotes immortalization and alters cell cycle and growth kinetics, but does not alter prostatic differentiation and morphogenesis. J Biol Chem. 727 (46): 44475-84, 2002. PMID: 12191999. 

3. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang YZ, Hayward SW, Cunha GR, Cardiff RD, Shen MM,  Abate-Shen C. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Research. 62: 2999-3004, 2002. PMID: 12036903.         



1. Wang YZ, Hayward SW, Cao M, Thayer K, Cunha GR. Cell differentiation lineage in the prostate. Differentiation. 68: 270-279, 2001. 

2. Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, GustafssonJA, Cunha GEvidence That Epithelial and Mesenchymal Estrogen Receptor-a Mediate Effects of Estrogen on Prostatic Epithelium. Developmental Biology. 229: 432-442, 2001. PMID: 11150243

3. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GParacrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death and Differentiation. 8(2): 192-200, 2001. PMID: 11313721. 

4. Settle S, Marker PC, Gurley K, Sinha A, Thacker A, Wang YZ, Higgins K, Cunha GR, Kingsley DM. The BMP family member GDF7 is required for seminal vesicle growth, branching morphogenesis, and cytodifferentiation.  Developmental Biology. 234: 138-150, 2001. PMID: 11356025. 

5. Wang YZ, Sudilovsky D, Zhang B, Haughney PC, Rosen MA, Wu DS, Cunha TW, Dahiya R, Cunha GR, Hayward SW. A Human Prostatic Epithelial Model of Hormonal Carcinogenesis. Cancer Research. 61: 6064-6072, 2001. PMID: 11507055. 

6. Cunha GR, Wang YZ, Hayward SW, Risbridger GP. Estrogenic effects on prostatic differentiation and carcinogenesis. Reproduction Fertility and Development. 13: 285-296, 2001. PMID: 11800167.  

7. Hayward SW, Wang YZ, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. Malignant Transformation In A Non-Tumorigenic Human Prostatic Epithelial Cell Line. Cancer Research. 61: 8135-8142, 2001. PMID: 11719442. 

8. Phillips JL, Hayward SW, Wang YZ, Vasselli J, Pavlovich C, Padilla-Nash H, Pezullo JR, Ghadimi BM, Grossfeld GD, Rivera A, Linehan WM, Cunha GR, Ried T. The Consequences of Chromosomal Aneuploidy on Gene Expression Profiles in a Cell Line Model for Prostate Carcinogenesis. Cancer Research. 61: 8143-8149, 2001. PMID: 11719443.       



1. Wong YC, Wang YZ, Lee JSK, Tam NC, Lee D. Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the Noble rat. Tumor Biolology. 21: 328-336, 2000. PMID: 11006573. 



1. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate. 35: 165-17, 1998. 

2. Wong YC, Wang YZ, Tam NC. The prostate gland and prostate carcinogenesis. New Trends in Microanatomy. Italian Journal of Anatomy and Embryology. 103(4): 237-252, 1998. 



1. Tam NNC, Wang YZ, Wong YC. The influence of mesenchyme of neonatal seminal vesicle and embryonic urogenital sinus on the morphological and functional cytodifferentiation of Dunning prostatic adenocarcinoma: Roles of growth factors. Urologic Oncology. 3: 85-9, 1997. PMID: 21227091. 

2. Wang YZ, Wong YC. Oncogenes and tumor suppressor genes in prostate cancer: A review. Urologic Oncology. 3: 41-46, 1997.  PMID: 21227058. 



Books & Chapters


1. Tumor Dormancy and Recurrence (YZ Wang, F Crea Eds), Springer-Nature International Publishing, 2017 (Edited/Editing)

2. Patient-Derived Xenograft Models (YZ Wang, D Lin, PW Gout Eds), Springer-Nature International Publishing, 2017 (Edited/Editing)

3. Lin D, Wang YZ, Gout PW. Prospectives (Lin D, Gout PW, Wang YZ, eds) Springer-Nature International Publishing (In press)

4. Lin D, Wang X, Gout PW, Wang YZ, Patient-Derived Tumor Xenografts: Historical Background. In Molecular and Translational Medicine (Lin D, Gout PW, Wang YZ., eds) Springer-Nature International Publishing, 2017 (In press)

5. Ricke WA, Williams K, Palapattu G, Wang YZ, Cunha GR. Hormonal carcinogenesis: Roles of estrogens. In The Molecular Basis of Human Cancer (Coleman, W. B., ed) Vol. Part V, Springer International Publishing, pp 307-322, 2017



1. Cochrane DR, Lin D, Dellaire G, Halvorsen EC, Berman, JN, Wang YZ, Huntsman D, Bennewith KL. Animal Models of Metastasis. In Genomic Instability and Cancer Metastasis Springer International Publishing, pp 95-123, 2015.

2. How to Write and Publish a Biomedical Paper in English. (JT Xie, LH Xie, Eds YZ Wang, Asso Eds), Second Edition, Science Press, Beijing, 2015 (Edited/Editing).



1. Gleave M, Cox M, Wang YZ, Cell biology of prostate cancer and molecular targets. In Drug Management of Prostate Cancer. (Figg, William D.; Chau, Cindy H.; Small, Eric J. Eds.) Humana Press, pp 1-24, 2010.



1. How to Write and Publish a Biomedical Paper in English. JT Xie Ed, Science Press, Beijing, 2009 (In Chinese)



1. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska V, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Current Cancer Drug Targets, 6, pp 455-489, 2006.



1. Ricke WA, Wang YZ, Kurita T, Hayward SW, Cunha GR. Hormonal and stromal regulation of normal and neoplastic prostatic development. In: Developmental Biology of Neoplastic Growth; Alvaro, M-C. (Ed), Springer-Verlag, New York, NY. pp 183-215, 2005.



2. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal micro-environment in carcinogenesis of the prostate. In: Prostate and renal cancer, benign prostatic hyperplasia, erectile dysfunction and basic research: An update. Bangma, C. H. and Newling, D. W. W. (Ed), Parthenon Publishing Group, New York. pp 155-171, 2003.



1. Wang YZ, Cunha GR, Hayward SW. In vitro and in vivo models of prostate cancer. In: American Cancer Society Atlas of Clinical Oncology. Prostate Cancer. P. R. Carroll and G. D. Grossfeld eds. BC Decker Inc, Hamilton, London. pp 68-81, 2002.

2. Hayward SW, Wang YZ, Day ML. Rescue and Isolation of Rb-deficient Prostate Epithelium by Tissue Recombination. In: Methods in molecular biology 218 Cancer Cell Signaling: Methods and Protocols. Ed Terrian, D.M. Humana Press, Totowa, NJ. pp 17-34, 2002.



1. Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. International Review of Cytology. Jeon KW Ed, Academic Press, 199: 65-116, 2000.



Back to Main Page